In fact, IAPP‐GI was found to be a nanomolar inhibitor of non‐native insulin aggregation.11d Importantly, as expected for a native interaction partner, IAPP‐GI–insulin interactions do not interfere with insulin function.11d Thus, the functional profile of IAPP‐GI comprises potent anti‐amyloid activity toward Aβ, IAPP, and insulin in combination with IAPP‐like bioactivity, which makes this peptide a promising lead for anti‐amyloid drugs in both AD and T2D, also in combination with insulin‐based treatments. The gene discussed is IAPP; the disease is type 2 diabetes mellitus.